Drug Profile
Research programme: cholesterol absorption inhibitors - Lipideon Biotechnology
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Lipideon Biotechnology AG
- Class Small molecules
- Mechanism of Action Cholesterol absorption inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypercholesterolaemia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hypercholesterolaemia in Switzerland (PO)
- 25 Mar 2010 Preclinical development is ongoing in Switzerland
- 30 Nov 2005 Preclinical trials in Hypercholesterolaemia in Switzerland (unspecified route)